ASX Indices

ASX 20 ASX 50 ASX 100 ASX 200 ASX 300 All Ordinaries

Stock Scans

Top Gainers Top Losers 52 Week Highs 52 Week Lows Highest Turnover Trading Halts DRPs Director Changes Fundamentally Sound

Commodities

Iron Ore Crude Oil Gold Silver Copper Lithium Uranium

Popular Pages

List of ASX Companies Highest Dividend Yield Upcoming Dividends Broker Consensus ASX Announcements Director Transactions ASX Sectors ASX ETFs ASX Short Sale Data Cboe Funds Australian Dollar

Plans & Portfolios

ASX Top 5 Portfolio Free & Supporter Plans

Home /

ASX

/ BOT /Axcess Iv Patent Approved In China

Sensitive ASX Announcement

Axcess IV Patent Approved in China

Published: 01/10/12, 12:06pm (AEST)•2 pages

Botanix Pharmaceuticals Ltd

BOT:ASX•Healthcare

Recent BOT Announcements

Price Sensitive only

ASX Indices

ASX 20 ASX 50 ASX 100 ASX 200 ASX 300 All Ordinaries All ASX Indices ≫

Commodities

Iron Ore Crude Oil Gold Silver Copper All Commodities ≫

Investment Scans

Highest Dividend Yield Broker Consensus

Popular Pages

List of ASX Companies Upcoming Dividends Director Transactions ASX Sectors ASX ETFs ASX Short Sale Data ASX Announcements Cboe Funds Australian Dollar

News

Latest News Authors Editorial Process

Stats & Downloads

Data Downloads Market Statistics

Resources

Trading Hours History of the ASX

Editors Picks

How to Buy Shares in Australia Dividend Yield Basics The Basics of Franking Credits Top 10 Investment Movies & Documentaries

Our Network

Livewire Markets

About Us Careers Privacy FSG Terms Of Use Advertising Contact Us

About Us Careers Advertising Contact Us

FSG Terms Of Use Privacy

Market Index and its data suppliers accept no responsibility for any claim, loss or damage whatsoever as a result of information on this website or services.

The Market Index website is owned by FinTech Equity Pty Ltd (ACN: 637 943 803) AFSL #521588

Factual Information Only: The Market Index website and all content, advertisements and other material contained on our website is factual information only. We are not financial advisers and none of the content on our website should be interpreted as financial advice. Nothing on our website is intended to imply a recommendation or opinion about a financial product or class of financial products. Before you make an investment decision based on any of the information contained on our website, please consult a qualified financial adviser or stockbroker.

All content is provided “as is” and not intended for trading purposes.

Copyright © 2026 Market Index